Oct. 23, 2025 -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 21,023,337 shares of its common stock and pre-funded warrants to purchase up to 3,226,458 shares of its common stock (the “Offering”). The offering price of each share of common stock is $8.66. The offering price of each pre-funded warrant is $8.659, w

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels Phase 2 data support both three-week and four-week dosing regimens for efdoralprin alfa - a potentially s

Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent Biofrontera AG. New earnout structure reduces payment rate to 12%–15% of U.S. net sales from 25%–35%. Closing releases final $2.5 million of $11 million financing led by existing investors Rosalind Advisors and AIGH Capital Management, which is expected to fund Biofrontera Inc. to profitability. Oct. 23, 2025 -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofron

Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521Trial showed reduction in annual cumulative steroid dose vs placebo through Week 52; safety profile consistent with known profile of Cosentyx1Data highlight potential of Cosentyx as novel targeted PMR treatment, second most common inflammatory disease in adults ≥502, with limited options available Basel, October 22, 2025 – Novartis today announced that Cosentyx® (secuk

Ingelheim, Germany Approval is based on results from Phase III FIBRONEER™-IPF trial, which showed statistically significant improvements in the absolute change from baseline in Forced Vital Capacity at 52 weeks with nerandomilast 18 mg and 9 mg versus placebo in adults with idiopathic pulmonary fibrosis (IPF)1,2Nerandomilast was included in the priority review by the Centre for Drug Evaluation (CDE) of the NMPA in January this year, and was recently granted FDA approval in the United States.

Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up to 24 hours after onset) – a population with no approved drug options. Scp776 was safe and well-tolerated, with no increase in serious adverse events versus placebo. Scp776 leverages Silver Creek’s proprietary Smart Growth Factor™ platform to selectively deliver a growth factor (IGF-1) to injured cells, representing a novel targeted biologic approach to stroke therapy. Oct. 23, 2025 --

Oct. 22, 2025 -- ProPhase Labs Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, announced today that its pivotal clinical study by Hartley et al. (2025) validating the BE-Smart™ esophageal cancer test has been accepted for publication in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association. This milestone marks a crucial turning point as ProPhase moves from validation

October 21, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. (“Purchaser”), a cash tender offer (the “Offer”) to purchase all of the issued and outstanding common shares (“Common Shares”) of Merus N.V. (Nasdaq: MRUS) (“Merus”) for $97.00 per Common Share in cash (the “Offer Consideration”), less any applicable withholding taxes and without interest. The Offer is being made pursuant to the previously announ

Oct. 20, 2025 -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the publication of a U.S. patent application by the United States Patent and Trademark Office. The patent relates to an innovative combination therapy of MEAI

Oct. 22, 2025 -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental-stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, has engaged Strategic Investor Relations, LLC, a premier investor relations firm, to enhance Curanex’s visibility in the financial community and support its ongoing efforts to engage and educate current and potential investors about the Company’s innovative pipeline and strategic i